Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.

 

Condition Intervention Phase
Onychomycosis Drug: AN2690 Phase 1
Phase 2

 
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis

Date of article/Start date of trial: 15 May 2008

Trial Phase: Phase 2

clinical Trials Gov ID: NCT00679601

Trial status: Completed

Back to New Antifungals